In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Aridis Pharmaceuticals (ARDS), with a price target of $22.00. The company’s shares closed last Friday at $7.38.
According to TipRanks.com, Byrnes has 0 stars on 0-5 stars ranking scale with an average return of -11.3% and a 33.7% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Opiant Pharmaceuticals, Adamas Pharmaceuticals, and Flexion Therapeutics.
Currently, the analyst consensus on Aridis Pharmaceuticals is a Strong Buy with an average price target of $16.67.
See today’s analyst top recommended stocks >>
Aridis Pharmaceuticals’ market cap is currently $64.34M and has a P/E ratio of -2.70. The company has a Price to Book ratio of -10.54.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in San Jose, CA.
